Metastatic disease from uveal melanoma: treatment options and future prospects

Uveal melanoma represents ∼85% of all ocular melanomas and up to 50% of patients develop metastatic disease. Metastases are most frequently localised to the liver and, as few patients are candidates for potentially curative surgery, this is associated with a poor prognosis. There is currently little published evidence for the optimal management and treatment of metastatic uveal melanoma and the lack of effective therapies in this setting has led to the widespread use of systemic treatments for patients with cutaneous melanoma. Uveal and cutaneous melanomas are intrinsically different diseases and so dedicated management strategies and therapies for uveal melanoma are much needed. This review explores the biology of uveal melanoma and how this relates to ongoing trials of targeted therapies in the metastatic disease setting. In addition, we consider the options to optimise patient management and care.

• Publication year

  2016

• Venue

  British Journal of Ophthalmology

• Publication date

  2016-08-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/bjophthalmol-2016-309034PMID 27574175PMCID 5256122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The use of pembrolizumab for the treatment of metastatic uveal melanoma

  2016cited by this paper
• Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)

  2015cited by this paper
• Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma

  2015cited by this paper
• Abstract 4262: PRAME as a biomarker for a new molecular subclass of uveal melanoma

  2015cited by this paper
• Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture.

  2015cited by this paper
• A phase 2 study of tremelimumab in patients with advanced uveal melanoma

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Uveal Melanoma UK National Guidelines.

  2015cited by this paper
• Isolated Hepatic Perfusion for Ocular Melanoma Metastasis: Registry Data Suggests a Survival Benefit

  2014cited by this paper
• Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

  2014cited by this paper
• Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• Dabrafenib Therapy for Advanced Melanoma

  2014cited by this paper
• Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

  2014cited by this paper
• Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations

  2014cited by this paper
• Clinical application of adoptive T cell therapy in solid tumors

  2014cited by this paper
• Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients.

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Assessment of overall survival from time of metastastasis in mucosal, uveal, and cutaneous melanoma.

  2014cited by this paper
• Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial.

  2014cited by this paper
• Metastatic melanoma to the liver: A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options

  2014cited by this paper
• Adjuvant Therapy of Uveal Melanoma: Current Status

  2014cited by this paper
• Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma

  2013cited by this paper
• Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death

  2013cited by this paper
• Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3

  2013cited by this paper
• Treatment of metastatic uveal melanoma with intravenous fotemustine

  2013cited by this paper
• Single nucleotide polymorphism array analysis of uveal melanomas reveals that amplification of CNKSR3 is correlated with improved patient survival.

  2013cited by this paper
• Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.

  2013cited by this paper
• SF3B1 mutations are associated with alternative splicing in uveal melanoma.

  2013cited by this paper
• Current and emerging treatment options for uveal melanoma

  2013cited by this paper
• Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma

  2013cited by this paper
• Radioembolization as Locoregional Therapy of Hepatic Metastases in Uveal Melanoma Patients

  2013cited by this paper
• KRAS mutation: should we test for it, and does it matter?

  2013cited by this paper
• Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes.

  2013cited by this paper
• Clinical activity of ipilimumab for metastatic uveal melanoma

  2013cited by this paper
• Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.

  2013cited by this paper
• Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).

  2013cited by this paper
• BEVATEM: Phase II study of bevacizumab (B) in combination with temozolomide (T) in patients (pts) with first-line metastatic uveal melanoma (MUM): Final results.

  2013cited by this paper
• Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

  2012cited by this paper
• The genetics of uveal melanoma: an emerging framework for targeted therapy

  2012cited by this paper
• Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture

  2012cited by this paper
• Ipilimumab in the treatment of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience.

  2012cited by this paper
• Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance

  2012cited by this paper
• Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients.

  2012cited by this paper
• Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways

  2012cited by this paper
• Collaborative Ocular Oncology Group Report No. 1: Prospective Validation of a Multi-Gene Prognostic Assay in Uveal Melanoma

  2012cited by this paper
• MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients

  2012cited by this paper
• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

  2012cited by this paper
• Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.

  2012cited by this paper
• Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study

  2012cited by this paper
• Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice

  2011cited by this paper
• Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers

  2011cited by this paper
• Uveal melanoma: trends in incidence, treatment, and survival.

  2011cited by this paper
• A Melanoma Molecular Disease Model

  2011cited by this paper
• Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma

  2011cited by this paper
• Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

  2011cited by this paper
• Mutations in GNA11 in uveal melanoma.

  2010cited by this paper
• The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

  2010cited by this paper
• Genotypic Profiling of 452 Choroidal Melanomas with Multiplex Ligation-Dependent Probe Amplification

  2010cited by this paper
• Locoregional management of hepatic metastasis from primary uveal melanoma.

  2010cited by this paper
• A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma.

  2010cited by this paper
• Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas

  2010cited by this paper
• Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.

  2010cited by this paper
• Liver Resection for Metastatic Melanoma with Postoperative Tumor-Infiltrating Lymphocyte Therapy

  2009cited by this paper
• Effectiveness of treatments for metastatic uveal melanoma.

  2009cited by this paper
• Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes.

  2009cited by this paper
• The 7th edition AJCC staging system for eye cancer: an international language for ophthalmic oncology.

  2009cited by this paper
• Targeted therapy for uveal melanoma.

  2008cited by this paper
• Oncogenic mutations in GNAQ occur early in uveal melanoma.

  2008cited by this paper
• Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi

  2008cited by this paper
• Hepatic arterial chemoembolization for management of metastatic melanoma.

  2008cited by this paper
• Incidence of uveal melanoma in Europe.

  2007cited by this paper
• AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

  2007cited by this paper
• The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: V. Twelve-Year Mortality Rates and Prognostic Factors: COMS Report No. 28

  2007cited by this paper
• Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

  2007cited by this paper
• High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma.

  2006cited by this paper
• Vascular endothelial growth factor a in eyes with uveal melanoma.

  2006cited by this paper
• The association between host susceptibility factors and uveal melanoma: a meta-analysis.

  2006cited by this paper
• The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28.

  2006cited by this paper
• Immunohistochemical expression of phospho-Akt in uveal melanoma

  2005cited by this paper
• Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis.

  2005cited by this paper
• Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

  2005cited by this paper
• Incidence of noncutaneous melanomas in the U.S.

  2005cited by this paper
• c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target?

  2004cited by this paper
• Dissecting karyotypic patterns in malignant melanomas: Temporal clustering of losses and gains in melanoma karyotypic evolution

  2004cited by this paper
• Very long-term prognosis of patients with malignant uveal melanoma.

  2003cited by this paper
• Absence of BRAF and NRAS mutations in uveal melanoma.

  2003cited by this paper
• Absence of Mutations of the BRAF Gene and Constitutive Activation of Extracellular-Regulated Kinase in Malignant Melanomas of the Uvea

  2003cited by this paper
• Mode of presentation and time to treatment of uveal melanoma in Finland

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15.

  2001cited by this paper
• Deregulation of the Rb and p53 pathways in uveal melanoma.

  2000cited by this paper
• Adoptive T Cell Immunotherapy of Human Uveal Melanoma Targeting gp1001

  2000cited by this paper
• The National Cancer Data Base report on cutaneous and noncutaneous melanoma

  1998cited by this paper
• BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression

  1998cited by this paper
• Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

  1997cited by this paper
• Dysplastic Nevi are a Risk Factor for Uveal Melanoma

  1996cited by this paper

• Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases.

  2026cites this paper
• Tumeurs oculaires

  2026cites this paper
• Tumour control, eye retention and visual acuity after radiotherapy for choroidal melanoma

  2026cites this paper
• Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art

  2026cites this paper
• Mutations with prognostic value in uveal melanoma. Analytical study of variants detected by targeted NGS.

  2026cites this paper
• Uveal melanoma survival prediction system: a multi-center database study

  2026cites this paper
• Surgical Interventions Improve Survival in Patients with Metastatic Uveal Melanoma

  2025cites this paper
• [How do doctors communicate results of genomic testing and its prognostic impact on uveal melanoma patients? Results of a qualitative study].

  2025cites this paper
• Diagnosis of metastatic melanoma in the liver. where can the primary tumor be found?

  2025cites this paper
• Clinical and Proteomic Insights into a Cytokine Release Syndrome Triggered by Tebentafusp in a Metastatic Uveal Melanoma Patient: Case Report

  2025cites this paper
• Donors With Previous Malignancy: When Is It Safe to Proceed With Organ Transplantation?

  2025cites this paper
• Efficacy and safety of robotic Cyberknife radiotherapy in uveal melanoma: a systematic review and meta-analysis

  2025cites this paper
• Non-Cutaneous Melanoma: Biology, Clinical Management, Current Therapy, and Future Directions in Treatment.

  2025cites this paper
• Does volume change of the spleen correlate with the therapy response in uveal melanoma patients with liver metastases undergoing hepatic artery infusion chemotherapy?

  2025cites this paper
• Current Treatment of Uveal Melanoma

  2025cites this paper
• The clinical benefit of adding radiotherapy to ipilimumab in patients with melanoma brain metastasis: a systematic review and meta-analysis

  2025cites this paper
• BAP1 Loss on Immunocytochemistry and Its Association With Monosomy 3 in Uveal Melanoma Fine‐Needle Aspirations

  2025cites this paper
• Melanoma uveal con metástasis gástricas. Reporte de caso

  2025cites this paper
• Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis.

  2025cites this paper
• Degradable Starch Microsphere Transarterial Chemoembolization as Salvage Therapy in Patients with Uveal Melanoma Liver Metastases.

  2025cites this paper
• Exploring recent advances in signaling pathways and hallmarks of uveal melanoma: a comprehensive review

  2025cites this paper
• A novel FTO-targeting nanodrug induces disulfidptosis and ameliorates the suppressive tumor immune environment to treat uveal melanoma.

  2025cites this paper
• Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion.

  2025cites this paper
• Surgical management of pulmonary metastases secondary to uveal melanoma: a case series.

  2025cites this paper
• N6-methyladenosine: a key regulator in ocular disease mechanisms and treatment

  2025cites this paper
• Uncovering the molecular signature of feline diffuse iris melanoma through transcriptomic analysis of disease severity

  2025cites this paper
• Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study

  2025cites this paper
• ZEB1 and Uveal Melanoma Invasiveness

  2025cites this paper
• Chromosomal 3p loss and 8q gain drive vasculogenic mimicry via HIF-2α and VE-cadherin activation in uveal melanoma

  2025cites this paper
• Elevated Lactic Acid Levels in the Aqueous Humor May Be an Indicator of Uveal Melanoma.

  2025cites this paper
• Clinical applications of circulating tumor cells in metastasis and therapy

  2025cites this paper
• Chelidonine inhibits melanoma cell malignancy by inactivating TLR4/NF-κB and PI3K/AKT signaling pathways

  2025cites this paper
• Precision prognostic model for uveal melanoma: nomogram prediction and comparison with AJCC system

  2025cites this paper
• Uncertainty and hope in people with metastatic uveal melanoma in the era of immunotherapy and targeted treatments: a theory-based qualitative study

  2025cites this paper
• Allele-specific depletion of GNAQQ209L via siRNA or an rAAV2-shRNA vector induces selective toxicity in GNAQQ209L uveal melanoma cells

  2025cites this paper
• Advances in Positron Emission Tomography/Computed Tomography for Diagnosing and Managing Primary Posterior Uveal Melanoma

  2025cites this paper
• Global trends and emerging insights in ocular tumor-associated metabolites: a bibliometric and visualization analysis

  2025cites this paper
• Bibliometric analysis of immunotherapy in treatment of uveal melanoma

  2025cites this paper
• Photosensitive virus-like mesoporous silica for enhanced uveal melanoma internalization and photodynamic therapy

  2025cites this paper
• Metastatic Melanoma Prognosis Prediction Using a TC Radiomic-Based Machine Learning Model: A Preliminary Study

  2025cites this paper
• Erianin inhibits cell migration and induces apoptosis by inhibiting VEGF-α/PI3K/AKT signaling pathway in malignant melanoma

  2025cites this paper
• Renal oncocytoma with liver metastasis: a case report with genetic analysis and literature review

  2025cites this paper
• Cytokine profiles in the aqueous humor of uveal melanoma: implications for tumor progression and radiation response

  2025cites this paper
• Radiotherapy has a survival advantage over surgery in patients with choroidal melanoma: a retrospective cohort study of 6,871 patients

  2025cites this paper
• Is there a role of surgical resection for uveal malignant melanoma liver metastases: report of two cases

  2025cites this paper
• The m6A hypermethylation-induced PIR overexpression regulates H3K4me3 and promotes Tumorigenesis of Uveal Melanoma.

  2025cites this paper
• Commentary on “B7-H3-Targeted CAR-T therapy with iCas9 for uveal melanoma liver metastases: Strengths and suggestions for enhancement”

  2025cites this paper
• Uveal Melanoma UK national guidelines: 2023 update.

  2025cites this paper
• Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma

  2025cites this paper
• Metastases from uveal melanoma may lack S100 expression: A clinico-pathologic and immunohistochemical study with emphasis on potential causes and diagnostic implications.

  2025cites this paper
• Oxidative stress-related genes in uveal melanoma: the role of CALM1 in modulating oxidative stress and apoptosis and its prognostic significance

  2025cites this paper
• Cell Death of Tumor Melanocytes and Treatment Options

  2025cites this paper
• Hypoxia-related lncRNA correlates with prognosis and immune microenvironment in uveal melanoma

  2024cites this paper
• Malignant Transformation of a Choroidal Nevus

  2024cites this paper
• Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

  2024cites this paper
• Microdissection of Distinct Morphological Regions Within Uveal Melanomas Identifies Novel Drug Targets

  2024cites this paper
• Evaluation of electrical impedance spectroscopy of bovine eyes for early detection of uveal melanoma

  2024cites this paper
• Single-cell RNA sequencing reveals key molecular drivers and immune landscape in uveal melanoma: implications for targeted therapy and prognostic modeling

  2024cites this paper
• Azacytidine treatment affects the methylation pattern of genomic and cell-free DNA in uveal melanoma cell lines

  2024cites this paper
• Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases

  2024cites this paper
• Differentiating Choroidal Melanomas and Nevi Using a Self-Supervised Deep Learning Model Applied to Clinical Fundoscopy Images

  2024cites this paper
• ZNF197-AS1/miR-425/GABARAPL1 axis: a novel regulatory mechanism in uveal melanoma

  2024cites this paper
• Unlocking Intracellular Oncology Targets: The Unique Role of Antibody-Based T-Cell Receptor Mimic (TCRm) Therapeutics in T-Cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs)

  2024cites this paper
• Are histomorphological patterns a predictor for survival in uveal melanoma patients with hepatic metastases undergoing hepatic artery infusion chemotherapy?

  2024cites this paper
• Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma

  2024cites this paper
• TRP channel-related LncRNAs, AC092535.4 and LINC01637, as novel prognostic biomarkers for uveal melanoma

  2024cites this paper
• Current therapeutic strategies for the treatment of ocular melanoma

  2024cites this paper
• Chimeric Antigen Receptor T Cell with an Inducible Caspase 9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting.

  2024cites this paper
• Melatonin Receptor Expression in Primary Uveal Melanoma

  2024cites this paper
• Participation of suicide gene extracellular vesicles in metastasis prevention.

  2024cites this paper
• Gq/G11 oncogenic mutations promote PD-L1 expression and suppress tumor immunity.

  2024cites this paper
• Artesunate attenuates the tumorigenesis of choroidal melanoma via inhibiting EFNA3 through Stat3/Akt signaling pathway

  2024cites this paper
• Modulating DNA damage response in uveal melanoma through embryonic stem cell microenvironment

  2024cites this paper
• Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma

  2024cites this paper
• The multiple roles of autophagy in uveal melanoma and the microenvironment

  2024cites this paper
• What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life

  2024cites this paper
• Uveal melanoma: the value of molecular genetic testing for early detection of metastatic disease. Clinical case

  2024cites this paper
• Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

  2024cites this paper
• Novel frameless LINAC radiosurgery solution for uveal melanoma

  2024influential citation
• A concept-based interpretable model for the diagnosis of choroid neoplasias using multimodal data

  2024cites this paper
• From oncogenes to tumor suppressors: The dual role of ncRNAs in fibrosarcoma.

  2024cites this paper
• Pathological and Molecular Diagnosis of Uveal Melanoma

  2024cites this paper
• Melanoma biology and treatment: a review of novel regulated cell death-based approaches

  2024cites this paper
• Uveal melanoma: Recent advances in immunotherapy

  2024cites this paper
• Expression and functional significance of phosphoenolpyruvate carboxykinase 1 in uveal melanoma

  2024cites this paper
• hHEPATO-Cy5, a Bimodal Tracer for Image-Guided Hepatobiliary Surgery

  2024cites this paper
• Ambient ultraviolet radiation and ocular melanoma incidence in the United States, 2000−2019

  2024cites this paper
• Anxiety, depression and fear of cancer recurrence in uveal melanoma survivors and ophthalmologist/oncologist communication during survivorship in France – protocol of a prospective observational mixed-method study

  2024cites this paper
• Recent Advancements in Management for Non-Colorectal, Non-Neuroendocrine Hepatic Metastases.

  2024cites this paper
• The role of monoglyceride lipase gene in promoting proliferation, metastasis, and free fatty acid accumulation in uveal melanoma cells

  2024cites this paper
• Eye and orbital malignancies: An overview

  2023cites this paper
• Cross-Platform Identification and Validation of Uveal Melanoma Vitreous Protein Biomarkers

  2023cites this paper
• Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.

  2023cites this paper
• Iris Melanoma: Review of Clinical Features, Risks, Management and Outcomes.

  2023cites this paper
• Analysis of uveal melanoma scRNA sequencing data identifies neoplastic-immune hybrid cells that exhibit metastatic potential

  2023cites this paper
• Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma

  2023cites this paper
• High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

  2023cites this paper
• Radiation Therapy for Ocular Melanoma – a Narrative Review with Insides from TRIUMF, Canada’s Only Proton Beam Therapy Center

  2023cites this paper
• Next‐generation sequencing of uveal melanoma with clinical and histological correlations: Prognostic value of new mutations in the PI3K/AKT/mTOR pathway

  2023cites this paper
• Decoding tumor heterogeneity in uveal melanoma: basement membrane genes as novel biomarkers and therapeutic targets revealed by multi-omics approaches for cancer immunotherapy

  2023cites this paper